Hyundai Pharmaceutical Co., LTD.
11
0
0
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 11 trials
100.0%
+13.5% vs industry average
18%
2 trials in Phase 3/4
0%
0 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
HDDO-1756 Bio Equivalence Study
Role: lead
BPDO-1603 Intervention Trial in Patients With Moderate-to-severe Alzheimer's Disease
Role: lead
HDDO-1801 Intervention Trial
Role: lead
HDDO-1614 Bio Equivalence Study
Role: lead
HDDO-1614 Intervention Trial
Role: lead
Change From Baseline to Chronic Kidney Disease Patient Before and After Administration Drug
Role: lead
Compare the Efficacy and Safety of Surfolase CR Tablet With Surfolase Capsule in Patients With Acute Bronchitis
Role: lead
To Evaluate Safety and the Pharmacokinetic Characteristics After Oral Administration of HT-003 Compared With Choline Alfoscerate Capsule in Healthy Adult Male Volunteers
Role: lead
Compare Safety and Pharmacokinetic Properties of Surfolase Capsule(Acebrophylline 100mg) and Surfolase CR(200mg)
Role: lead
Study to Evaluate the Effect of Food on the Pharmacokinetics of Surfolase CR Tablet in Healthy Volunteers
Role: lead
Study To Compare Safety and Pharmacokinetic Properties of Surfolase Capsule and HT-002-01 in Healthy Male Volunteers
Role: lead
All 11 trials loaded